Xtant Medical Holdings, Inc.

  • Moat Score
  • Safety Score
  • Market Cap $52.75M
  • PE -3
  • Debt $21.89M
  • Cash $7.09M
  • EV $67.55M
  • FCF -$17.28M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$17.59M
EBIT-$13.92M
ROE-38%
ROA-14%
FCF-$17.28M
Equity$45.73M
Growth Stability1
PE-3
PB1.15
P/FCF-3.05
P/S0.46
Price/Cash0.13
Debt/Equity0.48
Debt/FCF-1.27
Net Margins-15%
Gross Margins61%
Op. Margins-12%
Sales Growth YoY12%
Sales Growth QoQ-7%
Sales CAGR-1%
FCF CAGR0%
Equity CAGR11%
Earnings Growth YoY-154%
Earnings Growth QoQ30%
Sales CAGR 5Y14%
Equity CAGR 5Y22%
Earnings CAGR 3Y35%
Sales CAGR 3Y35%
Equity CAGR 3Y24%
Market Cap$52.75M
Revenue$113.86M
Assets$98.88M
Total Debt$21.89M
Cash$7.09M
Shares Outstanding131.88M
EV67.55M
Moat Score3%
Safety Score65%
Working Capital37.74M
Current Ratio2.12
Gross Profit$69.33M
Shares Growth 3y20%
Equity Growth QoQ2%
Equity Growth YoY-16%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts.

SEC Filings

Direct access to Xtant Medical Holdings, Inc. (XTNT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Xtant Medical Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Xtant Medical Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Xtant Medical Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Xtant Medical Holdings, Inc..

= -$173M
012345678910TV
fcf-$17M-$17M-$17M-$17M-$17M-$17M-$17M-$17M-$17M-$17M-$17M-$173M
DCF-$16M-$14M-$13M-$12M-$11M-$9.8M-$8.9M-$8.1M-$7.3M-$6.7M-$67M
Value-$173M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins-30%-4%-22%-63%-97%-13%-13%-9%-15%1%-15%
ROA--8%-5%-36%-129%-5%-2%-7%-11%-1%-14%
ROE--24%276%89%160%19%-48%-16%-25%1%-38%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF--9.92-5.97-63.76141.53-59.08-14.21-7.03-1.69-1.56-1.27
Debt over Equity-3.3512.7-17.09-2.37-1.9-1.732.230.380.350.330.48
Growth Stability----------1

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-68%52%-8%-13%-10%-18%4%5%58%14%
Earnings YoY growth--79%796%169%34%-88%-15%-31%75%-108%-
Equity YoY growth--214%-180%730%-25%1%-133%113%11%50%22%
FCF YoY growth-49%78%-89%-127%-320%76%-26%324%54%-